309 related articles for article (PubMed ID: 24067135)
1. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.
Ali S; Olszewski AJ
Leuk Lymphoma; 2014 Jul; 55(7):1570-7. PubMed ID: 24067135
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
3. Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors.
Xavier AC; Armeson KE; Hill EG; Costa LJ
Cancer; 2013 Sep; 119(18):3385-92. PubMed ID: 23797978
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma.
Chang ET; Lau EC; Mowat FS; Teta MJ
Cancer Causes Control; 2017 Sep; 28(9):971-979. PubMed ID: 28755241
[TBL] [Abstract][Full Text] [Related]
5. Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies.
Xavier AC; Costa LJ
Leuk Lymphoma; 2015; 56(8):2339-43. PubMed ID: 25393805
[TBL] [Abstract][Full Text] [Related]
6. Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma.
Chowdhry AK; McHugh C; Fung C; Dhakal S; Constine LS; Milano MT
Cancer; 2015 May; 121(9):1436-45. PubMed ID: 25572913
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996-2015.
Juntikka T; Malila N; Ylöstalo T; Merikivi M; Jyrkkiö S
Acta Oncol; 2020 May; 59(5):574-581. PubMed ID: 31910680
[No Abstract] [Full Text] [Related]
8. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
Baras N; Dahm S; Haberland J; Janz M; Emrich K; Kraywinkel K; Salama A
Br J Haematol; 2017 Apr; 177(2):226-242. PubMed ID: 28106907
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases.
Laurent C; Do C; Gourraud PA; de Paiva GR; Valmary S; Brousset P
Medicine (Baltimore); 2015 Jun; 94(25):e987. PubMed ID: 26107683
[TBL] [Abstract][Full Text] [Related]
10. A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma.
Chowdhry AK; Fung C; Chowdhry VK; Bergsma D; Dhakal S; Constine LS; Milano MT
Leuk Lymphoma; 2018 May; 59(5):1180-1187. PubMed ID: 28862484
[TBL] [Abstract][Full Text] [Related]
11. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.
Guru Murthy GS; Szabo A; Hamadani M; Fenske TS; Shah NN
Oncologist; 2019 Nov; 24(11):1488-1495. PubMed ID: 31467178
[TBL] [Abstract][Full Text] [Related]
12. Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.
Rossi C; Jégu J; Mounier M; Dandoit M; Colonna M; Daubisse-Marliac L; Trétarre B; Ganry O; Guizard AV; Bara S; Bouvier V; Woronoff AS; Monnereau A; Casasnovas O; Velten M; Troussard X; Maynadié M
Leuk Lymphoma; 2015; 56(10):2876-82. PubMed ID: 25641432
[TBL] [Abstract][Full Text] [Related]
13. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma.
Saarinen S; Pukkala E; Vahteristo P; Mäkinen MJ; Franssila K; Aaltonen LA
J Clin Oncol; 2013 Mar; 31(7):938-43. PubMed ID: 23284040
[TBL] [Abstract][Full Text] [Related]
14. Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.
Tadmor T; Liphshitz I; Silverman B; Polliack A
Hematol Oncol; 2017 Dec; 35(4):599-607. PubMed ID: 27238496
[TBL] [Abstract][Full Text] [Related]
15. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
[TBL] [Abstract][Full Text] [Related]
16. Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype.
Amber KT; Bloom R; Nouri K
Am J Clin Dermatol; 2016 Feb; 17(1):71-7. PubMed ID: 26386881
[TBL] [Abstract][Full Text] [Related]
17. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
Hisada M; Chen BE; Jaffe ES; Travis LB
J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
Lam CJ; Curtis RE; Dores GM; Engels EA; Caporaso NE; Polliack A; Warren JL; Young HA; Levine PH; Elmi AF; Fraumeni JF; Tucker MA; Morton LM
J Clin Oncol; 2015 Oct; 33(28):3096-104. PubMed ID: 26240221
[TBL] [Abstract][Full Text] [Related]
19. Nodular lymphocyte-predominant Hodgkin lymphoma.
Savage KJ; Mottok A; Fanale M
Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Mortality in Children and Adolescents with Hodgkin's Lymphoma: A Surveillance, Epidemiology and End Results Analysis.
Amini A; Murphy B; Cost CR; Garrington TP; Greffe BS; Liu AK
J Adolesc Young Adult Oncol; 2016 Jun; 5(2):181-6. PubMed ID: 26959398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
